Pfizer provides abrocitinib, an update to the regulatory schedule for XELJANZ

0

Similar title :
Pfizer Updates US FDA Review of Abrocitinib and XELJANZ
Pfizer Announces Update on US FDA Review of Abrocitinib and XELJANZ® Filings
Pfizer offers abrocitinib, government XELJANZ timeline update

Keywords:

Pfizer,Tofacitinib,Food and Drug Administration,Atopic dermatitis,Prescription Drug User Fee Act,Janus kinase inhibitor,Pfizer, Tofacitinib, Food and Drug Administration, Atopic dermatitis, Prescription Drug User Fee Act, Janus kinase inhibitor,,,,

QU’EN PENSEZ-VOUS?

[comment]

PUB

Laisser un commentaire, votre avis compte!

[gs-fb-comments] [comment-form]